(ZVRA) Zevra Therapeutics, Inc. Business Model Canvas Research

Clinical research organizations are core to Zevra Therapeutics, Inc.’s Phase II execution, especially across idiopathic hypersomnia, narcolepsy, and stimulant use disorder. They add operational scale, site management, and data handling, helping Zevra move 3 active mid-stage programs faster and with lower fixed overhead than building a full in-house trial team.

• Support 3 Phase II programs
• Run sites and patient flow
• Handle trial data and compliance
• Reduce internal operating burden

Zevra Therapeutics, Inc. relies on contract manufacturers and packagers to make and ship approved products and clinical candidates, since biopharma production needs specialized equipment, GMP controls, and controlled-substance handling. In FY2025, this support was critical to keep supply steady for rare-disease therapies and late-stage programs.

• Protects quality and compliance
• Keeps supply continuity stable
• Supports specialty drug packaging
• Reduces manufacturing bottlenecks

Zevra Therapeutics, Inc. must keep FDA filings, labeling, pharmacovigilance, and CMC (chemistry, manufacturing, and controls) tight across its 2 approved U.S. therapies, MIPLYFFA and OLPRUVA. For controlled-substance and rare-disease products, strong quality systems cut launch delays, recall risk, and post-market compliance issues.

• FDA submissions stay on schedule
• Labeling matches approved use
• Safety signals are tracked fast
• CMC controls protect product quality

Zevra Therapeutics, Inc. advances a rare-disease portfolio by focusing on high-unmet-need CNS and orphan targets, then picking indications with clear differentiation and commercial upside. With 2 approved rare-disease therapies, MIPLYFFA for Niemann-Pick disease type C and OLPRUVA for urea cycle disorders, Zevra uses sequencing and capital allocation to shape long-term growth.

• Targets high-unmet-need CNS/rare diseases
• Picks differentiated, commercial assets
• Sequences programs and allocates capital

Zevra Therapeutics, Inc. relies on patents and license deals to protect exclusivity on approved and pipeline assets, which is key in specialty pharma where one lost year can mean a fast drop in pricing power. In 2025, Zevra reported $15.0 million in Q1 revenue and held $123.4 million in cash and equivalents, so protecting licensed rights is central to future value capture.

• Patent walls defend exclusivity
• Licenses add external assets
• Supports higher-margin pricing
• Critical for specialty pharma

Zevra Therapeutics, Inc. relies on small, specialized teams to move rare-disease assets from clinic to market. With 2 FDA-approved therapies in 2025, scientific, clinical, regulatory, and CMC experts are essential for trial design, filings, manufacturing control, and launch execution; commercial and medical staff then help convert approval into uptake.

Human capital is the key execution resource because rare-disease programs need cross-functional speed and precision, not broad headcount.

• Clinical teams shape trial design
• Regulatory teams manage filings
• CMC teams protect product quality
• Commercial teams support launch
• Medical teams support adoption

KP1077 targets idiopathic hypersomnia and narcolepsy, while KP879 targets stimulant use disorder, giving Zevra Therapeutics, Inc. exposure to two CNS areas with few effective options and high unmet need. This pipeline can broaden Zevra Therapeutics, Inc. beyond approved products and capture larger sleep and addiction markets as clinical data mature.

• KP1077: sleep disorders
• KP879: stimulant use disorder
• Expands beyond approved products
• Targets major CNS unmet needs

Zevra Therapeutics, Inc. brings niche know-how in tightly regulated markets where ADHD, pain, and stimulant-related drugs often sit under DEA Schedule II-V controls. That matters because harder access rules, prior auth, and abuse-risk checks can slow launches; strong execution helps build doctor and payer trust.

• Fits complex, regulated therapies
• Supports access and reimbursement
• Builds confidence with physicians
• Helps manage abuse-risk scrutiny

Zevra Therapeutics, Inc. uses specialty pharmacy fulfillment support to manage controlled-channel ordering, dispensing, and patient onboarding for products like AZSTARYS and APADAZ. This setup helps tighten safety checks and compliance, while improving fill coordination for therapies that need close handling.

• Controls ordering and dispensing.
• Supports patient onboarding.
• Improves safety and compliance.
• Fits AZSTARYS and APADAZ.

Healthcare stakeholders need clear product info and safety follow-up, so Zevra Therapeutics, Inc. must keep fast response channels for clinicians and patients. Strong post-market support helps build trust, improve adherence, and feeds pharmacovigilance and lifecycle management as products scale after launch.

• Fast clinician and patient responses
• Safety follow-up and reporting
• Adherence support after launch
• Feeds pharmacovigilance and lifecycle work

Zevra Therapeutics, Inc. uses digital outreach and medical education to reach specialty clinicians and rare-disease centers that field teams cannot cover often. These channels help explain product profile and trial data, and they support conference activity while staying efficient in small, high-value patient pools.

• Reaches hard-to-find specialty niches
• Explains trial data clearly
• Supports field and conference work
• Fits rare-disease awareness needs

Zevra Therapeutics, Inc. uses partner licensing to extend reach beyond its own sales base, which fits an asset-light specialty model. In 2024, the Company booked $15.6 million in product revenue, while collaboration and licensing structures help scale assets without matching that growth with a full commercial build.

• Extends commercialization reach
• Lowers operating burden
• Fits asset-light specialty strategy

KP879 targets patients with stimulant use disorder, a large unmet need with no FDA-approved drug therapy and rising care demand. In the U.S., SAMHSA has estimated millions of people with past-year stimulant misuse, so this segment will likely be reached through addiction specialists and behavioral health providers, making it a high-impact future market for Zevra Therapeutics, Inc.

• Large unmet need
• No approved drug therapy
• Uses specialty care channels
• High future market impact

Zevra Therapeutics, Inc. sells into three decision layers: prescribers start therapy, payers decide coverage, and health systems steer where and how patients get treated. That mix matters because access and utilization can shape sales more than patient demand alone.

For Zevra Therapeutics, Inc., these are the core economic customers for all approved and future products, since a single therapy can still face prior auth, formulary review, and institutional rules before a patient gets it.

• Prescribers drive first use.
• Payers control access and reimbursement.
• Health systems shape utilization pathways.

Zevra Therapeutics, Inc. carries steady regulatory and compliance costs because every filing, safety review, and audit check must stay ready for FDA and global rules. These costs include pharmacovigilance and quality systems, and in 2025 they remained a fixed part of running a specialty pharma business, often scaling with each new product, label change, and inspection cycle.

• Filing prep never stops
• Safety monitoring is ongoing
• Quality systems protect launches
• Compliance reduces product risk

Zevra Therapeutics, Inc. relies on external licensing and collaboration deals, so cost structure can include milestone payments, royalties, and shared development spend. In biotech, royalty rates often run in the high single digits to low teens, and these variable costs must be weighed against each program’s revenue potential and probability of approval.

• Milestones raise cash needs
• Royalties cut gross margin
• Shared R&D lowers upfront burn

KP879 could become a long-term revenue stream for Zevra Therapeutics, Inc. if it wins approval in stimulant use disorder, a field with no FDA-approved medicines and millions of affected patients in the U.S. alone. Commercial sales would still hinge on regulatory success and payer access, so near-term value is optionality, not booked revenue.

• No approved revenue today
• High unmet need, large patient pool
• Sales depend on FDA and reimbursement

Zevra Therapeutics, Inc. can earn non-product cash from licensing deals through upfront fees, development milestones, and sales royalties. For a specialty biotech, even one partner deal can fund R&D and lower dilution pressure; in its model, this stream matters because external partners can turn pipeline progress into cash before product sales scale.

• Upfront cash starts the deal.
• Milestones pay on progress.
• Royalties pay on sales.
• Helps fund R&D and cut dilution.